VERSION WITH MARKINGS TO SHOW CHANGES MADE

7. (Amended) The method according to [any one of claims 1 to 6] claim 1, wherein said first nucleic acid comprises RNA.

11. (Amended) The method according to [any one of claims 1, 2, or] claim 8, wherein said first nucleic acid comprises DNA and said second nucleic acid comprises RNA.

13. (Amended) The method according to [any one of claims] claim 8 [to 12], wherein said first nucleic acid and/or gene product thereof and said second nucleic acid and/or gene product thereof are obtained from the same kind of organelle.

14. (Amended) The method according to claim 1 [or 2], wherein said first nucleic acid comprises RNA and said second nucleic acid comprises DNA.

19. (Amended) The method according to claim 17 [or 18], wherein said medicament is used for treatment of a chronic disease.

20. (Amended) The method according to [any one of claims 16 to 19] claim 17, wherein said introducing a medicament to said organism comprises introducing said medicament to an organism free from side-effects at a first time said medicament is introduced to said organism.

21. (Amended) The method according to [any one of claims 16 to 21] claim 17, wherein said therapeutic activity comprises a therapeutic activity against an HIV-related disease and/or a tumor-related disease.

22. (Amended) The method according to [any one of claims 16 to 21] claim 17, wherein said [candidate compound or] medicament comprises a nucleoside and/or nucleotide analogue.

24. (Amended) The method according to [any one of claims 16 to 23] claim 17, wherein said [candidate compound or] medicament comprises AZT, ddI, ddC, d4T, 3TC and/or tenofofir.

25. (Amended) The method according to [any one of claims 16 to 24] claim 17, wherein said determining comprises determining said relative ratio prior to said introducing said [candidate compound or] medicament.

26. (Amended) The method according to [any one of claims 16 or 20 to 25] claim 16, further comprising determining selective activity of said candidate compound against said cellular organism.

30. (Amended) The method according to [any one of claims] claim 1 [to 29], wherein said relative ratio is determined in the same assay.

32. (Amended) The method according to claim 30 [or 31], wherein said relative ratio is determined directly by dividing an amount of said first nucleic acid and/or gene product by an amount of said second nucleic acid and/or gene product.

33. (Amended) The method according to claim 30 [or 31], wherein said relative ratio is determined directly by dividing an amount of said second nucleic acid and/or gene product by an amount of said first nucleic acid and/or gene product.

34. (Amended) The method according to [any one of claims 1 to 33] claim 1, wherein said relative ratio is determined by comparison with a reference curve.

35. (Amended) The method according to [any one of claims 1 to 34] claim 1, wherein said first nucleic acid and/or gene product thereof and said second nucleic acid and/or gene product thereof are obtained from a peripheral blood mononuclear and/or a fibroblast.

36. (Amended) A diagnostic kit comprising at least one means for performing a method according to [any one of claims 1 to 35] claim 1.

39. (Amended) The method according to [any one of claims] claim 16 [or 20 to 35], further comprising preparing said candidate compound as a medicament, an herbicide, an insecticide, an anti-parasiticum, a cystostatic agent or a cytotoxic agent.

40. A medicament, a herbicide, an insecticide, an anti-parasiticum, a cystostatic agent or a cytotoxic agent obtainable or selectable by the method according to [any one of claims] claim 16[or 20 to 35].